14.2亿元！华润医药拟出售所持天麦生物17.87%股权

Core Viewpoint - China Resources Pharmaceutical plans to sell approximately 17.87% stake in Tianmai Biotechnology for a base price of 1.42 billion yuan, valuing the company at around 8 billion yuan [1][3]. Company Overview - Tianmai Biotechnology, established in 2010, focuses on the development and introduction of diabetes-related products and technologies, providing comprehensive management services for diabetes patients [3]. - The company has expanded its business to include CDMO services, such as the research and delivery of recombinant proteins and the development and commercial production of sterile biological preparations [3]. Strategic Partnerships - Tianmai Biotechnology has collaborated with an Israeli company to establish a joint laboratory in Yavne, Israel, successfully developing raw materials and formulations for human insulin and insulin analogs [3]. Compliance and Standards - The company's core platform has received national special support, and its production base complies with international GMP standards [3]. Innovative Business Model - Tianmai Biotechnology has disrupted traditional pharmaceutical sales models by creating a diabetes management model suitable for grassroots healthcare in China [3].